STOCK TITAN
  1. Home
  2. News
  3. BIOR

Biora Therapeutics Inc - BIOR STOCK NEWS

Welcome to our dedicated news page for Biora Therapeutics (Ticker: BIOR), a resource for investors and traders seeking the latest updates and insights on Biora Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biora Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biora Therapeutics's position in the market.

News
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
Rhea-AI Summary
Biora Therapeutics, Inc. announces the issuance of a new patent related to the company’s BioJet™ platform for oral, systemic delivery of biotherapeutics. The patent covers key parameters for liquid jet delivery of drugs to the gastrointestinal tract, showing promising results in preclinical testing. Biora holds a strong patent position with multiple issued patents and pending applications, positioning them as a leader in innovative therapeutic delivery technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.65%
Tags
none
-
News
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
Rhea-AI Summary
Biora Therapeutics, Inc. shares positive interim results from the phase 1 clinical trial of BT-600, a drug-device combination for ulcerative colitis treatment. The trial demonstrates successful pharmacokinetic endpoints, localized drug delivery to the colon, reduced systemic drug exposure, and improved colonic tissue exposure. The NaviCap platform shows potential for enhanced efficacy and reduced toxicity risks. The MAD portion of the trial is ongoing, with final results expected in late Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
clinical trial
-
News
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
Biora Therapeutics, Inc. (BIOR) successfully closed a registered direct offering of 5,454,548 shares of common stock at $1.10 per share, along with a private placement of warrants. The total gross proceeds amounted to approximately $6,000,000. H.C. Wainwright & Co. served as the exclusive placement agent. The net proceeds will be utilized for operational support, ongoing clinical trials, further development of oral biotherapeutics platforms, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
offering
News
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
Biora Therapeutics, Inc. (BIOR) announces a registered direct offering of 5,454,548 shares of common stock at $1.10 per share and a concurrent private placement of unregistered warrants. The offering is priced at-the-market under Nasdaq rules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-33.18%
Tags
offering
-
News
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
Rhea-AI Summary
Biora Therapeutics, Inc. (BIOR) reports successful results from the single-ascending dose (SAD) portion of the BT-600 clinical trial, demonstrating targeted drug delivery to the colon with lower systemic drug levels. The company is progressing well with the remainder of the trial and BioJet platform. Financially, Biora reduced net debt by 75% in 2023 and raised $19.8 million through note exchanges. The company aims to conclude the BT-600 trial in Q2 2024 and plans a clinical study for ulcerative colitis patients in H2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.03%
Tags
earnings
-
News
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
Rhea-AI Summary
Biora Therapeutics, Inc. (Nasdaq: BIOR) will report financial results and provide a corporate update for Q4 and full year 2023 on March 26, 2024. A webcast and conference call will be hosted by the company's management. Details for the call are provided for interested parties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
conferences earnings
News
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
Rhea-AI Summary
Biora Therapeutics, Inc. secures $3 million in nondilutive capital through the monetization of legacy assets and $2.8 million in new capital from a convertible notes exchange with Context Capital. The company has significantly reduced its debt by over $80 million and attracted $19.8 million in new capital from institutional investors. Biora continues to optimize its capital structure and advance its therapeutic programs, with upcoming data release from the SAD portion of its phase 1 clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.72%
Tags
none
-
News
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
Rhea-AI Summary
Biora Therapeutics, Inc. completes SAD cohorts for BT-600 clinical study, with MAD dosing to start in March. The drug-device combination aims to treat ulcerative colitis by delivering tofacitinib directly to the colon for improved efficacy and reduced adverse events. Data from the SAD portion to be shared in March corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.67%
Tags
clinical trial
-
News
Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium
Rhea-AI Summary
Biora Therapeutics, Inc. (Nasdaq: BIOR) will participate in the Inflammatory Bowel Disease Symposium hosted virtually by Canaccord Genuity Capital Markets on February 28, 2024. Ariella Kelman, M.D., Chief Medical Officer, will participate in the panel titled 'The Next Evolutionary Steps in Addressing IBD.'
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.57%
Tags
none
News
Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.
Rhea-AI Summary
Biora Therapeutics, Inc. (Nasdaq: BIOR) will participate in a virtual fireside chat hosted by H.C. Wainwright & Co. to discuss the company’s delivery platforms addressing significant therapeutics indications, including its first ongoing clinical trial. The event is scheduled for January 29, 2024, at 11:00 AM Eastern / 8:00 AM Pacific. Adi Mohanty, CEO, Ariella Kelman, M.D., CMO, and Eric d’Esparbes, CFO, will be the speakers. A live webcast and replay of the fireside chat session will be available through the Investor Relations section of the Biora website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
none
Stock BIOR logo
Biora Therapeutics Inc

Nasdaq:BIOR

BIOR Rankings

#5083 Ranked by Market Cap
#5308 Ranked by Stock Gains
N/A Ranked by Dividends

BIOR Stock Data

22.21M
13.75M
7.91%
64.14%
4.42%
Medical Laboratories
Health Care and Social Assistance
Link
US
San Diego

About BIOR

progenity helps patients and their families prepare for life, with medically relevant health information starting before conception, through pregnancy, childhood, and adulthood. using our highly-complex molecular diagnostic testing, healthcare providers can access the most advanced genomic technology to guide patient care at critical life stages.